Hepion Pharmaceuticals, Inc.
corporate_fare Company Profile
Hepion Pharmaceuticals, Inc. (OTC:CTRVP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CTRVP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for CTRVP spans 10-Q, 8-K, DEF 14C, SCHEDULE 13D/A.
Recent high-impact activity:
- Hepion 10-Q: $4.3M Cash, Going Concern Doubt, and Material Weaknesses Disclosed
- Hepion Acquires Gravitas Life Sciences in $4.25M Related-Party Deal, Names New CEO and CFO
- Hepion Dismisses Grassi & Co., Hires RRBB as New Auditor
- Hepion Approves 1-for-20 to 1-for-50 Reverse Split and 6x Increase in Authorized Shares
- Hepion Secures $500K Convertible Note with 12.5M Warrants from Gravitas Capital
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for CTRVP, detected from its recent SEC filings · based on capital-structure filings through 2026-08-04.
Private Placement Priced at Deep Discount · Warrants Add Further Dilution Overhang
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →